NEW YORK (GenomeWeb) – GenMark Diagnostics said after the market closed on Thursday that it has achieved CE marking for its ePlex BCID gram-positive and gram-negative panels.

The firm noted that with CE marking for the BCID-GP and BCID-GN panels, it has achieved the designation for its ePlex family of sepsis panels, which also includes the BCID Fungal Pathogen Panel that achieved the CE mark in April.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.